Sign In
Buy TBIO
$0.0530
+0 (+0%)
At Close: Jun 02, 2026
Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis
04:05pm, Wednesday, 25'th Sep 2024
Innovation Delivers High-Fidelity, Scalable, Non-Toxic On-Premises Biofoundry Capabilities Innovation Delivers High-Fidelity, Scalable, Non-Toxic On-Premises Biofoundry Capabilities
Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market
04:30pm, Tuesday, 10'th Sep 2024
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO) (“Telesis” or the “Company”), a leading provider of RNA and DNA solutions enabling researchers to accelerate thera
Telesis Bio Reports Second Quarter and First Half 2024 Financial Results
04:05pm, Wednesday, 07'th Aug 2024
SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, fle
Telesis Bio Reports First Quarter 2024 Financial Results
04:05pm, Thursday, 09'th May 2024
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flex
Telesis Bio Announces Reverse Stock Split
04:05pm, Monday, 06'th May 2024
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (the Company) (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through
SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated benchtop DNA and mRNA synthesis solutions, today announced a focus in strategy enabled by the comme
Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results
04:05pm, Thursday, 28'th Mar 2024
SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, fl
Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results
09:15am, Monday, 26'th Feb 2024
SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, fle
Why Is Telesis Bio (TBIO) Stock Up 29% Today?
08:44am, Friday, 23'rd Feb 2024
Telesis Bio (NASDAQ: TBIO ) stock is on the rise Friday as the synthetic biology company's shares experienced heavy trading this morning. Shares of TBIO stock are off to a strong start on Friday with
Telesis Bio Reports Third Quarter 2023 Financial Results
04:22pm, Monday, 13'th Nov 2023
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the third quarter o
Telesis Bio to Report Third Quarter Financial Results on Monday, November 13, 2023
09:00am, Tuesday, 07'th Nov 2023
SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2023
Telesis Bio Announces Commercial Release of Cell-free Amplification Kit for Generation of Transfection-scale DNA
12:00pm, Friday, 03'rd Nov 2023
New Kit offers BioXp automation workflow from candidate sequence to amplified DNA in days New Kit offers BioXp automation workflow from candidate sequence to amplified DNA in days
Telesis Bio Announces Commercial Release of BioXp® NGS Library Prep Kit for WGS
03:48pm, Thursday, 28'th Sep 2023
New Kit expands suite of NGS Library Prep solutions on the BioXp® System Enabling Speed and Efficiency for Whole genome sequencing (WGS) applications with the Automated Molecular Biology Workstation
Telesis Bio Appoints William J. Kullback Chief Financial Officer
04:05pm, Tuesday, 29'th Aug 2023
SAN DIEGO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, has named William J. Kullback as its Chief Financial Off
Telesis Bio, Inc. (TBIO) Q2 2023 Earnings Call Transcript
04:02pm, Friday, 11'th Aug 2023
Telesis Bio, Inc. (NASDAQ:TBIO ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Todd Nelson - Founder, Chief Executive Officer Eric Esser - President, Chief Operating
